LDL-C-Lowering Therapy Lerochol Gains FDA Approval The FDA approved Lerochol, a monthly PCSK9 inhibitor, for adults with hypercholesterolemia to reduce LDL-C levels alongside diet and exercise.

#Lerochol prefilled syringes will be available in the spring of 2026.

Read More: https://bit.ly/4jACOFQ

💊FDA Approval Update | #Lerochol (#Lerodalcibep-liga)
🔸A third-generation #PCSK9 inhibitor that can reduce #LDL-C in #hypercholesterolemia
🌟Achieved approximately 50% reduction in apolipoprotein B levels + a 24% reduction in lipoprotein(a) in Phase III trial